<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644809</url>
  </required_header>
  <id_info>
    <org_study_id>17825</org_study_id>
    <secondary_id>J3F-MC-EZCA</secondary_id>
    <nct_id>NCT04644809</nct_id>
  </id_info>
  <brief_title>A Study of LY3561774 in Participants With Dyslipidemia</brief_title>
  <official_title>A Single-Ascending and Repeat-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3561774</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3-part study. In Parts A and B, the main purpose is to evaluate the safety and&#xD;
      tolerability of the study drug known as LY3561774 in participants with dyslipidemia (high&#xD;
      blood fat levels). How the body processes the study drug and the effect of the study drug on&#xD;
      blood fat levels will also be investigated. Part C will mainly evaluate the safety and&#xD;
      tolerability of LY3561774 as well as how the body processes the study drug in Japanese&#xD;
      participants. The study may last up 52, 56 and 28 weeks for each participant in Parts A, B&#xD;
      and C, respectively. There are up to 22, 26 and 16 visits in Parts A, B and C, respectively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">April 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Week 53</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3561774</measure>
    <time_frame>Predose through Day 8</time_frame>
    <description>PK: AUC[0-tlast] of LY3561774</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of LY3561774</measure>
    <time_frame>Predose through Day 8</time_frame>
    <description>PK: Cmax of LY3561774</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time of Maximum Observed Concentration (Tmax) of LY3561774</measure>
    <time_frame>Predose through Day 8</time_frame>
    <description>PK: Tmax of LY3561774</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Change From Baseline in Fasting Triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Predose through Week 53</time_frame>
    <description>PD: Change From Baseline in Fasting TG and LDL-C</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>LY3561774 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of LY3561774 administered subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3561774 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat doses of LY3561774 administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3561774 (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of LY3561774 administered SC in Japanese Participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A, B &amp; C)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3561774</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3561774 (Part A)</arm_group_label>
    <arm_group_label>LY3561774 (Part B)</arm_group_label>
    <arm_group_label>LY3561774 (Part C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Placebo (Part A, B &amp; C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For Parts A and B, have a fasting triglyceride (TG) level greater than or equal to (≥)&#xD;
             150 milligram/deciliter (mg/dL) and less than 500 mg/dL, as well as low density&#xD;
             lipoprotein cholesterol (LDL-C) level greater than or equal to (≥) 70 mg/dL&#xD;
&#xD;
          -  For Part C, participants should be first-generation Japanese origin.&#xD;
&#xD;
          -  Have a body mass index (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m²)&#xD;
&#xD;
          -  Male participants must agree to adhere to contraception restrictions and female&#xD;
             participants must not be able to get pregnant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have taken any prescription medications that are for lowering serum TGs within the&#xD;
             past 2 months (use of statins is allowed if the dose has been stable for 8 weeks)&#xD;
&#xD;
          -  Have Type 1 diabetes&#xD;
&#xD;
          -  Are currently participating in or completed a clinical trial within the last 30 days&#xD;
&#xD;
          -  Are heavy alcohol drinkers or heavy cigarette smokers&#xD;
&#xD;
          -  Have donated blood of more than 500 millilitres (mL) in the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-252-0700</phone>
    </contact>
    <investigator>
      <last_name>David Nguyen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research, LLC</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qps-Mra, Llc</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/6o9PZPIhCp7DEVhxSrEnhY</url>
    <description>A Study of LY3561774 in Participants With Dyslipidemia</description>
  </link>
  <verification_date>November 1, 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

